Ask AI
AD at CTAD Podcast

CE / CME

Cognitive Conversations: Key Findings on Alzheimer’s Disease Presented at CTAD

Nurse Practitioners/Nurses: 0.75 Nursing contact hour, including 0.75 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: December 26, 2025

Expiration: December 25, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Real-world data demonstrating accuracy of the Lumipulse p-tau217/Aβ42 plasma assay, the first blood-based biomarker test FDA cleared for diagnosis of Alzheimer’s disease in May 2025, were presented at CTAD 2025. What is measured by this assay?

2.

Which statement summarizes topline results presented at CTAD 2025 from the phase III randomized placebo-controlled trials evoke and evoke+ for semaglutide treatment in patients with early-stage AD?